Rising Cancer Incidence Fuels Growth In Cancer Profiling Market: Powering Innovation and Expansion in the Cancer Profiling Market by 2025

Stay ahead with our updated market reports featuring the latest on tariffs, trade flows, and supply chain transformations.

What Is the Expected CAGR for the Cancer Profiling Market Through 2025?
The market size of cancer profiling has seen a swift expansion in the past few years. It is set to escalate from $13.48 billion in 2024 to $15.05 billion in 2025, with a compound annual growth rate (CAGR) of 11.6%. The surge during the historic timeframe can be credited to mounting incidence rates of cancer, advancements in precision medicine, acceptance of biomarkers in clinics, the evolution of targeted therapies and drug development, heightened awareness, and patient advocacy.

What's the Projected Size of the Global Cancer Profiling Market by 2029?
In the coming years, the market size of cancer profiling is anticipated to experience swift expansion. It is projected to elevate to $23.08 billion in 2029, escalating at a compound annual growth rate (CAGR) of 11.3%. The anticipated growth during the forecasted period could be accredited to factors such as AI integration, global research collaborations, the broadening scope of liquid biopsy applications, regulatory backing for precision medicine, and a heightened focus on early detection. Key trends during this projection period encompass the dominance of liquid biopsy, extensive genomic profiling, the emergence of immunoprofiling, the establishment of a cooperative data sharing network, and single-cell sequencing.

View the full report here:
https://www.thebusinessresearchcompany.com/report/cancer-profiling-global-market-report

Top Growth Drivers in the Cancer Profiling Industry: What's Accelerating the Market?
The escalation in the occurrence of cancer is anticipated to bolster the development of the cancer profiling market in the near future. The occurrence or frequency of cancer corresponds to the emergence of new instances of the disease in a certain populace within a defined timeframe. Factors like urbanization, a growing elderly population, shifting life patterns, environmental influences, and inheritable components have led to a surge in cancer incidents. Cancer profiling abets in delineating distinct molecular or genetic variations in a tumor, such as gene aberrations or alterations in tumor DNA, which prove to be beneficial in the cycle of cancer treatment. For instance, the American Cancer Society, a non-profit organization in the United States, projected that in 2022, the count of new cancer instances diagnosed and cancer-related deaths is expected to reach 1.9 million and 609,360 respectively. Therefore, the amplifying occurrences of cancer act as a propellant for the progression of the cancer profiling market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=9912&type=smp

What Trends Will Shape the Cancer Profiling Market Through 2029 and Beyond?
Prominent players in the cancer profiling market are concentrating on birthing innovations such as broad coverage. This type of test examines 517 cancer-associated genes across close to 30 distinct solid tumor types. The broad coverage essentially means extensive analysis of various genetic mutations, biomarkers, or molecular targets. To cite an example, in March 2022, Illumina, Inc., a biotechnology firm in the US, introduced the TruSight Oncology Comprehensive (TSO) test, signifying a remarkable progress in cancer diagnostics. A new in vitro diagnostic test in Europe informs about cancer mutations to steer patients towards specific therapies. It appraises 517 genes over nearly 30 solid tumor forms, studying both DNA and RNA. Delivering results in a swift four to five days, it is CE-marked complying with European quality standards and lessens the demand for multiple gene assays on different tissue samples.

What Are the Main Segments in the Cancer Profiling Market?
The cancer profiling market covered in this report is segmented -

1) By Technology: Immunoassays, PCR (Polymerized Chain Reaction), NGS (Next-Generation Sequencing), Microarrays, In-Situ Hybridization
2) By Biomarker Type: Genomic Biomarkers, Protein Biomarkers
3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Melanoma Cancer, Other Cancers
4) By Application: Research Applications, Clinical Applications, Screening, Diagnostics, Prognostics, Other Applications

Subsegments:
1) By Immunoassays: Enzyme-Linked Immunosorbent Assay (ELISA), Western Blotting, Luminex xMAP Technology, Radioimmunoassays
2) By PCR (Polymerase Chain Reaction): Quantitative PCR (qPCR), Digital PCR (dPCR), Reverse Transcription PCR (RT-PCR)
3) By NGS (Next-Generation Sequencing): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq)
4) By Microarrays: DNA Microarrays, RNA Microarrays, SNP Arrays
5) By In-Situ Hybridization: Fluorescence In-Situ Hybridization (FISH), Chromogenic In-Situ Hybridization (CISH)

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=9912&type=smp

Which Top Companies are Driving Growth in the Cancer Profiling Market?
Major companies operating in the cancer profiling market include Illumina Inc., Qiagen NV, NeoGenomics Inc., Sysmex Corporation, HTG Molecular Diagnostics Inc., Caris Life Sciences, NanoString Technologies Inc., Guardant Health Inc., Foundation Medicine Inc., Roche Diagnostics Corporation, F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Genscript Biotech Corporation, Tempus Labs Inc., Hologic Inc., Predictive Oncology Inc., Abbott Laboratories, Agilent Technologies Inc., PerkinElmer Inc., Siemens Healthineers, Genomic Health Inc., Natera Inc., ArcherDX Inc., Personal Genome Diagnostics Inc., Enzo Biochem Inc., Cancer Genetics Inc., OncoDNA SA, Ribomed Biotechnologies Inc., Biocartis Group NV, N-of-One Inc., Cynvenio Biosystems Inc., Inivata Ltd., Burning Rock Biotech Limited, PathAI Inc., GENEWIZ Inc., Genoptix Inc., Oncomine Dx Target Test, OmniSeq Comprehensive, Resolution Bioscience, OncoCyte Corporation

Which Regions Will Dominate the Cancer Profiling Market Through 2029?
North America was the largest region in the cancer profiling market in 2024. The regions covered in the cancer profiling market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=9912

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.